OSE Immunotherapeutics Reports Additional Positive Phase 2 Combi-TED Results
OSE Immunotherapeutics announced additional positive results from the randomized Phase 2 Combi-TED study of Tedopi (OSE2101) in metastatic non-small cell lung cancer.
Story updates
05:32:08 PM UTC
SquawkNews
Nantes, France, October 29, 2026 — 6:00pm CET — OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today reported final positive results from the Combi-TED academic…